Future directions in cardiovascular disease risk prediction

被引:0
|
作者
Doust, Jenny A. [1 ]
Bonner, Carissa [2 ]
Bell, Katy J. L. [2 ]
机构
[1] Univ Queensland, Ctr Longitudinal & Life Course Res, Sch Publ Hlth, Brisbane, Qld, Australia
[2] Univ Sydney, Fac Med & Hlth, Sydney Sch Publ Hlth, Sydney Med Sch, Sydney, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
ASSOCIATION TASK-FORCE; AMERICAN-COLLEGE; BLOOD-PRESSURE; NEW-ZEALAND; VALIDATION; MANAGEMENT; GUIDELINE; ADULTS; PREVENTION; MODELS;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Although the National Vascular Disease Prevention Alliance (NVDPA) guidelines were published in 2012, many individuals at high risk of cardiovascular disease (CVD) are not prescribed preventive medication or have CVD risk factors recorded. Better use of CVD risk prediction tools and targeting of medication could reduce CVD. Objective The aim of this article is to review recent developments in CVD risk prediction, including calculators developed in the USA, UK and New Zealand, and non-traditional tests for cardiovascular risk assessment. Discussion The Framingham Risk Equation explains much of the risk variance in the population but overestimates risk for a contemporary Australian population. Newer risk calculators show improvement in calibration. Individuals vary greatly in terms of whether they will find the potential benefits of taking medication worthwhile, and shared decision-making tools can help to clarify decision making.
引用
收藏
页码:488 / 494
页数:7
相关论文
共 50 条
  • [41] Brachial-Ankle PWV: Current Status and Future Directions as a Useful Marker in the Management of Cardiovascular Disease and/or Cardiovascular Risk Factors
    Tomiyama, Hirofumi
    Matsumoto, Chisa
    Shiina, Kazuki
    Yamashina, Akira
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2016, 23 (02) : 128 - 146
  • [42] Novel biomarkers for cardiovascular risk assessment: current status and future directions
    MacNamara, James
    Eapen, Danny J.
    Quyyumi, Arshed
    Sperling, Laurence
    FUTURE CARDIOLOGY, 2015, 11 (05) : 597 - 613
  • [43] Lifetime Risk Prediction in Cardiovascular Prevention: Wave of the Future?
    Gryn, Steven E.
    Hackam, Daniel G.
    CANADIAN JOURNAL OF CARDIOLOGY, 2013, 29 (02) : 142 - 143
  • [44] Preeclampsia: A Risk Factor for Future Cardiovascular Disease
    Bilhartz, T. D.
    Bilhartz, P. A.
    Bilhartz, R. D.
    Bilhartz, T. N.
    FIRST INTERNATIONAL CONGRESS ON CARDIAC PROBLEMS IN PREGNANCY (CPP), 2010, : 75 - 79
  • [45] Dose of aspirin in the treatment and prevention of cardiovascular disease: Current and future directions
    Hennekens, Charles H.
    Sechenova, Oksana
    Hollar, Danielle
    Serebruany, Victor L.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2006, 11 (03) : 170 - 176
  • [46] Macrophage Inflammation and Cardiovascular Disease in HIV: Mechanistic Insights and Future Directions
    Feinstein, Matthew J.
    Lloyd-Jones, Donald M.
    JOURNAL OF INFECTIOUS DISEASES, 2017, 215 (09): : 1343 - 1345
  • [47] Sense of Purpose in Life and Cardiovascular Disease: Underlying Mechanisms and Future Directions
    Eric S. Kim
    Scott W. Delaney
    Laura D. Kubzansky
    Current Cardiology Reports, 2019, 21
  • [48] Correction to: Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions
    Anum Saeed
    Kaustubh Dabhadkar
    Salim S. Virani
    Peter H. Jones
    Christie M. Ballantyne
    Vijay Nambi
    Current Atherosclerosis Reports, 2018, 20
  • [49] Diabetes and Cardiovascular Disease in Older Adults: Current Status and Future Directions
    Halter, Jeffrey B.
    Musi, Nicolas
    Horne, Frances McFarland
    Crandall, Jill P.
    Goldberg, Andrew
    Harkless, Lawrence
    Hazzard, William R.
    Huang, Elbert S.
    Kirkman, M. Sue
    Plutzky, Jorge
    Schmader, Kenneth E.
    Zieman, Susan
    High, Kevin P.
    DIABETES, 2014, 63 (08) : 2578 - 2589
  • [50] Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments
    Berinstein, Elliot
    Levy, Andrew
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (09) : 973 - 983